Understanding the investment opportunity
Inrobics is a spin-off from Carlos III Madrid University (UC3M), Spain specializing in social artificial intelligence applied to health, longevity, and education. The company develops Alma®, its proprietary technological platform designed to support, stimulate, and improve individuals’ physical, cognitive, and emotional well-being through social robots and virtual assistants.
Alma® is a modular, multimodal, hardware-agnostic artificial intelligence capable of integrating with various devices, such as social robots, tablets, or virtual avatars. The platform functions as an intelligent assistant that accompanies, motivates, and guides users through therapeutic, educational, or cognitive stimulation processes, adapting activities in real time and generating objective metrics for professionals. Inrobics’ differentiating value lies in its proprietary software, designed to be scalable and deployable across multiple devices and care environments.
Inrobics was created to address one of the main challenges facing healthcare and care systems: how to provide more care in a context of population aging, professional shortages, and increasing demand for long-term therapies. Its technology enables the intensification and extension of interventions beyond clinical settings, including patients’ homes, improving treatment adherence and optimizing professionals’ time without increasing care burdens.
Currently, the company operates in three main verticals:
- Health and rehabilitation, with solutions that enhance physical and cognitive therapies in hospitals, rehabilitation centers, and early intervention services.
- Longevity and home care, with intelligent support systems that stimulate physical and cognitive activity in older adults, both in care facilities and in their own homes.
- Special education, with cognitive stimulation and learning tools that improve motivation, attention, and the overall development of students.
After more than ten years of research and technological validation, Inrobics has completed the development phase and is now in commercial scaling. The company has already generated more than €500,000 in revenue, deployed over 20 centers, and impacted more than 1,000 users across clinical, educational, and social-healthcare settings. In addition, Inrobics is closing new contracts totaling over €800,000 in committed revenue for 2026 and maintains an active commercial pipeline exceeding €12 million, with ongoing projects in special education, care facilities, and home care.
Inrobics’ technology complies with major regulatory and quality standards, including CE marking as medical software, processes aligned with ISO 13485, and GDPR compliance, positioning it as a scalable, clinically validated solution set to transform the delivery of care, rehabilitation, and cognitive stimulation in the coming years.
The investment round in Inrobics is structured for new investors through an investment company that will be incorporated upon the successful closing of the round. There is one circumstance we need to highlight: if, when capital gains are generated, the investment company’s stake in Inrobics is below 5%, those capital gains will be subject to double taxation, due to the non-application of the corporate tax exemption. We will implement mechanisms to try to avoid this, but you should be aware of this circumstance.
Inrobics Team
CEO y Fundador
José Carlos Pulido Pascual
CEO y Fundador
CSO y Fundador
Fernando Fernández Rebollo
CSO y Fundador
CTO y Fundador
José Carlos González Dorado
CTO y Fundador
Grow Venture Partners
INVESTOR
Reasons to invest View more data
Inrobics represents an investment opportunity in a company that has surpassed the technological risk phase and is validated in real clinical environments.
The platform is proprietary, modular, and not dependent on specific hardware, which facilitates its adaptation to different use cases and geographic markets.
Proprietary and scalable technology
- Social artificial intelligence platform Alma®, modular and hardware-agnostic, capable of being deployed on social robots, tablets, or virtual assistants.
- Technology architecture designed to operate across multiple verticals (rehabilitation, longevity, and education) without technological redesigns.
- Medical software certified CE Class I, with regulatory evolution planned towards FDA.
Scientific and clinical validation
- Over 10 years of applied research in social robotics and artificial intelligence.
- Scientific publications in international journals (IEEE, Springer, Elsevier).
- Clinical results showing therapeutic adherence above 95% and a threefold increase in therapeutic intensity.
- Demonstrated reduction of up to 90% of the time professionals spend on repetitive tasks.
Commercial traction and real deployment
- >€500,000 in cumulative revenue.
- ~€16,000 in current MRR.
- More than 20 centers deployed across hospitals, early intervention centers, and care homes.
- Over 1,000 users directly impacted.
Solid pipeline and proven growth model
- Over €800,000 in contracts in the closing process for upcoming deployments.
- Active commercial pipeline exceeding €12 million, mainly with institutional clients.
- Growth strategy based on publicly funded innovation pilots that evolve into framework contracts and full network deployments.
Access to major institutional clients
- Growing presence in public administrations, hospitals, and socio-health centers, where the demand for scalable care solutions is structural.
- Collaborations with large private groups of care homes and home care providers, enabling large-scale deployments.
- Support from technology and service partners such as Telefónica or Inetum, acting as channels to reach major accounts and institutional projects.
Positioning in three high-growth markets
- Health and rehabilitation
- Longevity and home care
- Special education
This diversification allows multiplying the accessible market while maintaining a single technology base.
Institutional and ecosystem recognition
- Awards and reference programs: RETECH Comunidad de Madrid (Startup of highest impact), UNICEF Lab Winner, Lilly Emprende inHealth, CaixaImpulse, Mobile World Capital – The Collider, Fundación Once, among others.
Who is the reference investor?
Grow Venture Partners
INVESTOR
About Grow Venture Partners
Grow Venture Partners es un fondo de venture capital con sede en Barcelona especializado en deeptech y transferencia tecnológica. Su foco de inversión se centra en spin-offs científicas y tecnológicas con una fuerte base de propiedad intelectual, surgidas de universidades y centros de investigación. El fondo invierte en fases pre-seed y seed, con tickets entre 100.000 € y 2.000.000 €, apoyando proyectos con tecnología diferencial y potencial de escalabilidad internacional. Además del capital, Grow Venture Partners aporta acompañamiento estratégico en el proceso de transformación de tecnologías avanzadas en empresas escalables, apoyando a los equipos fundadores en áreas clave como estrategia de crecimiento, financiación y desarrollo de negocio. Su inversión en Inrobics refuerza la validación tecnológica del proyecto y su potencial para convertir investigación avanzada en soluciones con impacto real en el sector de la salud y los cuidados.- Investing in startups:20+ years
- BPs analyzed:5,000+
- Investments:21
- Exits:7
Beyond the technological value, we see a clear market opportunity. Health and social care systems face a structural challenge: a growing demand for care alongside a limited availability of professionals. Solutions that increase care capacity without raising costs will become increasingly necessary.
Inrobics combines this market opportunity with real validation: technology developed over more than a decade, initial deployments in real centers, and a growing commercial pipeline with public institutions and major operators in the social care sector.
Finally, we particularly value the founding team, which combines a deep scientific background with the ability to transform advanced research into a real and scalable product. This combination of technology, market, traction, and team is what led us to invest in the company."
It has also invested in...
Live
Chat
You need to be registered to view the content
This content is confidential and you must be registered with Startupxplore in order to access it.
Register meOpportunity analysis Last update Jul 7, 2026 10:23:45 AM
You need to be registered to view the content
This content is confidential and you must be registered with Startupxplore in order to access it.
Register meInvestor questions
The regulations governing Startupxplore's activity require that no investor is in possession of more information than the rest. Therefore, this section will provide answers to any questions asked by an investor about the opportunity.
If you have any doubts or questions about the startup, the process or any other aspect please write to us at coinversion@startupxplore.com
You need to be registered to view the content
This content is confidential and you must be registered with Startupxplore in order to access it.
Register meDocumentation
You need to be registered to view the content
This content is confidential and you must be registered with Startupxplore in order to access it.
Register me